JP2017528457A5 - - Google Patents

Download PDF

Info

Publication number
JP2017528457A5
JP2017528457A5 JP2017512783A JP2017512783A JP2017528457A5 JP 2017528457 A5 JP2017528457 A5 JP 2017528457A5 JP 2017512783 A JP2017512783 A JP 2017512783A JP 2017512783 A JP2017512783 A JP 2017512783A JP 2017528457 A5 JP2017528457 A5 JP 2017528457A5
Authority
JP
Japan
Prior art keywords
dosage form
unit dosage
abiraterone acetate
dose
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017512783A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017528457A (ja
Filing date
Publication date
Priority claimed from US14/707,922 external-priority patent/US20150246060A1/en
Application filed filed Critical
Priority claimed from PCT/US2015/050889 external-priority patent/WO2016044701A1/en
Publication of JP2017528457A publication Critical patent/JP2017528457A/ja
Publication of JP2017528457A5 publication Critical patent/JP2017528457A5/ja
Pending legal-status Critical Current

Links

JP2017512783A 2014-09-18 2015-09-18 酢酸アビラテロン製剤及び使用方法 Pending JP2017528457A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462052294P 2014-09-18 2014-09-18
US62/052,294 2014-09-18
US14/707,922 US20150246060A1 (en) 2013-03-15 2015-05-08 Abiraterone Acetate Formulation and Methods of Use
US14/707,922 2015-05-08
PCT/US2015/050889 WO2016044701A1 (en) 2014-09-18 2015-09-18 Abiraterone acetate formulation and methods of use

Publications (2)

Publication Number Publication Date
JP2017528457A JP2017528457A (ja) 2017-09-28
JP2017528457A5 true JP2017528457A5 (https=) 2018-10-18

Family

ID=55533897

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017512783A Pending JP2017528457A (ja) 2014-09-18 2015-09-18 酢酸アビラテロン製剤及び使用方法

Country Status (17)

Country Link
EP (1) EP3193857A4 (https=)
JP (1) JP2017528457A (https=)
KR (2) KR102617537B1 (https=)
CN (1) CN106687112A (https=)
AP (1) AP2017009804A0 (https=)
AU (1) AU2015317466A1 (https=)
BR (1) BR112017003219A2 (https=)
CA (1) CA2958316A1 (https=)
CO (1) CO2017002472A2 (https=)
EA (1) EA201790650A1 (https=)
IL (1) IL250270B (https=)
MD (1) MD20170048A2 (https=)
MX (1) MX2017003525A (https=)
PH (1) PH12017500239A1 (https=)
SG (1) SG11201701139YA (https=)
TN (2) TN2017000098A1 (https=)
WO (1) WO2016044701A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2863500T3 (es) 2015-04-10 2021-10-11 Capsugel Belgium Nv Formulaciones lipídicas de acetato de abiraterona
KR102771163B1 (ko) 2017-04-07 2025-02-25 엠에이에이 래보러토리스, 인코포레이티드 치료제의 용해도 및 생체이용률을 향상시키는 방법
WO2020151633A1 (en) * 2019-01-25 2020-07-30 Shenzhen Pharmacin Co., Ltd. Pharmaceutical compositions
JP7644713B2 (ja) 2019-03-06 2025-03-12 プロペラ セラピューティクス インコーポレイテッド アビラテロンプロドラッグ
CN110742870B (zh) * 2019-12-04 2021-04-20 武汉大学 醋酸阿比特龙制剂及其制备方法
CN111110646A (zh) * 2020-02-19 2020-05-08 纳兰迦(上海)生物医药科技有限公司 一种低规格醋酸阿比特龙口服制剂的处方及制备方法
CN113384542B (zh) * 2020-03-14 2024-03-29 鲁南制药集团股份有限公司 一种甾体cyp17抑制剂固体分散体的片剂及其制备方法
IL297338A (en) * 2020-04-16 2022-12-01 Tavanta Therapeutics Hungary Incorporated Methods and compositions for treating prostate cancer
UY39201A (es) * 2020-05-08 2021-11-30 Janssen Pharmaceutica Nv Tratamientos del cáncer de próstata con combinaciones de acetato de abiraterona y niraparib
EP3944860A1 (en) 2020-07-30 2022-02-02 Galenicum Health S.L.U. Abiraterone for use in a method of treating cancer
CN117120034A (zh) 2021-02-15 2023-11-24 普洛佩拉治疗公司 阿比特龙前药
KR20240044329A (ko) 2022-09-28 2024-04-04 한미약품 주식회사 아비라테론 아세테이트 및 프레드니솔론을 포함하는 경구용 복합정제
KR20240145412A (ko) 2023-03-27 2024-10-07 한미약품 주식회사 아비라테론 아세테이트 및 프레드니솔론을 포함하는 약제학적 제제 및 이의 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201401705VA (en) * 2009-04-24 2014-08-28 Iceutica Pty Ltd Production of encapsulated nanoparticles at commercial scale
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
WO2014009437A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Oxidation stability of abiraterone acetate
WO2014009436A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
WO2014009434A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
CN102743393A (zh) * 2012-07-27 2012-10-24 海南盛科生命科学研究院 一种含有醋酸阿比特龙的药物组合物及制备工艺
MX2015013247A (es) * 2013-03-15 2016-11-25 Iceutica Inc Formulacion de acetato de abiraterona.

Similar Documents

Publication Publication Date Title
JP2017528457A5 (https=)
ES2742525T3 (es) Composiciones de corticosteroides administradas oralmente
JP3145111B2 (ja) 炎症性腸疾患処置用経口組成物
EP2903620A1 (en) Progesterone containing oral dosage forms and kits
WO2003000263A1 (en) Rapid onset formulation
JP2020530832A (ja) 副腎皮質刺激ホルモン放出因子受容体拮抗薬
EP3911304A1 (en) Modified release tablet formulations containing phosphodiesterase inhibitors
WO2013134348A1 (en) Controlled-release solid dosage forms of mesalamine
CN103316026B (zh) 含芬特明和托吡酯的联合产品及其制备方法
CN113018273A (zh) 一种固体制剂及其制备方法和用途
CN105007902A (zh) 包含大量的两种丸粒的多颗粒药物组合物
JP2011506607A5 (https=)
CN104510853B (zh) 一种治疗妇女痛经的中药有效部位组合物及其用途
CN110035751A (zh) 一种维利帕尼缓控释药物组合物及其用途
WO2017100246A1 (en) Pharmaceutical formulations for treating skin disorders and methods for fabricating and using thereof
CN105106250B (zh) 一种灵芝总三萜组合物及其制备方法
US20230172875A1 (en) Extended release liquid compositions of guaifenesin
CN105663063B (zh) 甘草酸二铵和恩替卡韦的复方微丸片及其制备方法
CN101371825B (zh) 以丙酸氟替卡松为活性成分的口腔粘贴片
CN101371844B (zh) 以糠酸莫米松为活性成分的治疗口腔溃疡的粘贴片
TW200817012A (en) Peroral medicament form for contraception
JP2016513133A5 (https=)
WO2023067485A1 (en) Pharmaceutical combinations
Burggraaf et al. The gastrointestinal passage and release of beclomethasone dipropionate from oral delivery systems in ileostomy volunteers
TWI634909B (zh) Long-acting sustained-release medicine composition and preparation method thereof